Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Silvia Cerri, Francesca Siani & Fabio Blandini. (2017) Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias. Expert Opinion on Investigational Drugs 26:7, pages 777-791.
Read now
Read now
Jing Gan, Chen Qi & Zhenguo Liu. (2015) Roles of Ca2+/calmodulin-dependent protein kinase II in subcellular expression of striatal N-Methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats. Drug Design, Development and Therapy 9, pages 2119-2128.
Read now
Read now
Fabio Blandini & Marie-Therese Armentero. (2014) Dopamine receptor agonists for Parkinson's disease. Expert Opinion on Investigational Drugs 23:3, pages 387-410.
Read now
Read now
Panagiotis Bargiotas & Spyridon Konitsiotis. (2013) Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsychiatric Disease and Treatment 9, pages 1605-1617.
Read now
Read now
Articles from other publishers (50)
Sun Jing, Yaozong Yuan, Chiara Leuratti, Valentina Vaja & Carlo Cattaneo. (2023) Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers. Clinical Pharmacology in Drug Development 12:11, pages 1104-1113.
Crossref
Crossref
Ritam Bandopadhyay, Nainshi Mishra, Ruhi Rana, Gagandeep Kaur, Mohammed M. Ghoneim, Sultan Alshehri, Gulam Mustafa, Javed Ahmad, Nabil. A. Alhakamy & Awanish Mishra. (2022) Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Frontiers in Pharmacology 13.
Crossref
Crossref
Efthalia Angelopoulou, Yam Nath Paudel, Thomas Julian, Mohd Farooq Shaikh & Christina Piperi. (2020) Pivotal Role of Fyn Kinase in Parkinson’s Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?. Molecular Neurobiology 58:4, pages 1372-1391.
Crossref
Crossref
Aijuan Yan, Lu Song, Yu Zhang, Xijin Wang & Zhenguo Liu. (2021) Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway. Frontiers in Aging Neuroscience 12.
Crossref
Crossref
Mercè Pallàs, Santiago Vázquez, Coral Sanfeliu, Carles Galdeano & Christian Griñán-Ferré. (2020) Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson’s Disease: A New Therapeutic Strategy. Biomolecules 10:5, pages 703.
Crossref
Crossref
Maria Laura Ester Bianchi, Giulio Riboldazzi, Marco Mauri & Maurizio Versino. (2018) Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease. Neurological Sciences 40:2, pages 275-279.
Crossref
Crossref
Tonghui Su, Yi Lu, Yang Geng, Wei Lu & Yelin Chen. (2019) How could N-Methyl-D-Aspartate Receptor Antagonists Lead to Excitation Instead of Inhibition?. Brain Science Advances 4:2, pages 73-98.
Crossref
Crossref
Delphine Charvin, Therese Di Paolo, Erwan Bezard, Laurent Gregoire, Akihiro Takano, Guillaume Duvey, Elsa Pioli, Christer Halldin, Rossella Medori & François Conquet. (2018) An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates. Movement Disorders 33:10, pages 1619-1631.
Crossref
Crossref
Delphine Charvin. (2018) mGlu4 allosteric modulation for treating Parkinson's disease. Neuropharmacology 135, pages 308-315.
Crossref
Crossref
Yixian Huang, Haiyang Shu, Li Li, Tili Zhen, Junyan Zhao, Xianju Zhou & Weifeng Luo. (2018) L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats. ASN Neuro 10, pages 175909141881102.
Crossref
Crossref
Wen-Wen Wang, Man-Man Zhang, Xing-Ru Zhang, Zeng-Rui Zhang, Jie Chen, Liang Feng & Cheng-Long Xie. (2017) A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo. Frontiers in Neurology 8.
Crossref
Crossref
Juan-Juan Du & Sheng-Di Chen. (2017) Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease. Chinese Medical Journal 130:15, pages 1856-1866.
Crossref
Crossref
Nicolas Morin & Thérèse Di Paolo. 2017. mGLU Receptors. mGLU Receptors
183
205
.
Qiang Wang & Wangming Zhang. (2016) Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia. Frontiers in Neural Circuits 10.
Crossref
Crossref
Luca Loprete, Chiara Leuratti, Carlo Cattaneo, Mita M. Thapar, Colm Farrell & Marco Sardina. (2016) Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease. Pharmacology Research & Perspectives 4:5.
Crossref
Crossref
Rajib Paul & Anupom Borah. (2016) L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room. Biochimica et Biophysica Acta (BBA) - General Subjects 1860:9, pages 1989-1997.
Crossref
Crossref
Tanuja Bordia, Xiomara A. Perez, Jaime E. Heiss, Danhui Zhang & Maryka Quik. (2016) Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias. Neurobiology of Disease 91, pages 47-58.
Crossref
Crossref
Vincent A. Jourdain, Nicolas Morin, Laurent Grégoire, Marc Morissette & Thérèse Di Paolo. (2015) Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy. Journal of Neurosurgery 123:6, pages 1383-1393.
Crossref
Crossref
Danhui Zhang, Matthew McGregor, Tanuja Bordia, Xiomara A. Perez, J. Michael McIntosh, Michael W. Decker & Maryka Quik. (2015) α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Movement Disorders 30:14, pages 1901-1911.
Crossref
Crossref
Maryka Quik, Tanuja Bordia, Danhui Zhang & Xiomara A. Perez. 2015. Nicotine Use in Mental Illness and Neurological Disorders. Nicotine Use in Mental Illness and Neurological Disorders
247
271
.
Ah-Reum Doo, Seung-Nam Kim, Dae-Hyun Hahm, Hye Hyun Yoo, Ji-Yeun Park, Hyejung Lee, Songhee Jeon, Jongpil Kim, Seong-Uk Park & Hi-Joon Park. (2014) Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model. BMC Complementary and Alternative Medicine 14:1.
Crossref
Crossref
Yuh-Jiin I. Jong, Ismail Sergin, Carolyn A. Purgert & Karen L. O’Malley. (2014) Location-Dependent Signaling of the Group 1 Metabotropic Glutamate Receptor mGlu5. Molecular Pharmacology 86:6, pages 774-785.
Crossref
Crossref
John R. Atack, Brian C. Shook, Stefanie Rassnick, Paul F. Jackson, Kenneth Rhodes, Wilhelmus H. Drinkenburg, Abdallah Ahnaou, Paula te Riele, Xavier Langlois, Brian Hrupka, Patrick De Haes, Herman Hendrickx, Nancy Aerts, Koen Hens, Annemie Wellens, Jef Vermeire & Anton A. H. P. Megens. (2014)
JNJ-40255293, a Novel Adenosine A
2A
/A
1
Antagonist with Efficacy in Preclinical Models of Parkinson’s Disease
. ACS Chemical Neuroscience 5:10, pages 1005-1019.
Crossref
Crossref
Danhui Zhang, Matthew McGregor, Michael W. Decker & Maryka Quik. (2014)
The
α
7 Nicotinic Receptor Agonist ABT-107 Decreases l-Dopa–Induced Dyskinesias in Parkinsonian Monkeys
. Journal of Pharmacology and Experimental Therapeutics 351:1, pages 25-32.
Crossref
Crossref
Maryka Quik, Danhui Zhang, Xiomara A. Perez & Tanuja Bordia. (2014) Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacology & Therapeutics 144:1, pages 50-59.
Crossref
Crossref
Nicolas Morin & Thérèse Di Paolo. (2014) Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates. Frontiers in Neurology 5.
Crossref
Crossref
Barbara Picconi & Paolo Calabresi. (2014) Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?. Movement Disorders 29:6, pages 715-719.
Crossref
Crossref
Nicolas Morin, Vincent A. Jourdain, Marc Morissette, Laurent Grégoire & Thérèse Di Paolo. (2014) Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Neuropharmacology 79, pages 688-706.
Crossref
Crossref
Xiaoying Wang, Guiyun Cui, Xinxin Yang, Zunsheng Zhang, Hongjuan Shi, Jie Zu, Fang Hua & Xia Shen. (2014) Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease. Brain Research Bulletin 103, pages 60-65.
Crossref
Crossref
Danhui Zhang, Tanuja Bordia, Matthew McGregor, J. Michael McIntosh, Michael W. Decker & Maryka Quik. (2014) ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Movement Disorders 29:4, pages 508-517.
Crossref
Crossref
Carolyn A. Purgert, Yukitoshi Izumi, Yuh-Jiin I. Jong, Vikas Kumar, Charles F. Zorumski & Karen L. O'Malley. (2014) Intracellular mGluR5 Can Mediate Synaptic Plasticity in the Hippocampus. The Journal of Neuroscience 34:13, pages 4589-4598.
Crossref
Crossref
Michael J. Hurley, Michael J. Jackson, Lance A. Smith, Sarah Rose & Peter Jenner. (2013) Proteomic Analysis of Striatum from MPTP-Treated Marmosets (Callithrix jacchus) with l-DOPA-Induced Dyskinesia of Differing Severity. Journal of Molecular Neuroscience 52:2, pages 302-312.
Crossref
Crossref
Nicolas Morin & Thérèse Di Paolo. 2014. Adenosine Receptors in Neurology and Psychiatry. Adenosine Receptors in Neurology and Psychiatry
151
167
.
Giulia Ambrosi, Silvia Cerri & Fabio Blandini. 2014. Metabolism of Human Diseases. Metabolism of Human Diseases
29
33
.
A. Sampedro, E. Tarragón, J. E. Yuste, F. Ros-Bernal, V. Ortiz, C. M. Campuzano, A. Gómez, C. M. Ros, E. Fernández-Villalba & M. T. Herrero. 2014. Handbook of Neurotoxicity. Handbook of Neurotoxicity
1311
1340
.
Barbara Picconi & Paolo Calabresi. 2014. Levodopa-Induced Dyskinesia in Parkinson's Disease. Levodopa-Induced Dyskinesia in Parkinson's Disease
229
243
.
Nicolas Morin, Marc Morissette, Laurent Grégoire, Baltazar Gomez-Mancilla, Fabrizio Gasparini & Thérèse Di Paolo. (2013) Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys. Neuropharmacology 73, pages 216-231.
Crossref
Crossref
Joseph JankovicJoseph Jankovic. 2013. Parkinson’s Disease: Medical and Surgical Treatment. Parkinson’s Disease: Medical and Surgical Treatment
139
148
.
Marie Therese Fuzzati-Armentero, Cristina Ghezzi, Robert Nisticò, Adriano Oda & Fabio Blandini. (2013) Single or combined treatment with l-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells. Neuroscience Letters 552, pages 168-173.
Crossref
Crossref
Maryka Quik, Carla Campos, Tanuja Bordia, Jon-Paul Strachan, Jenny Zhang, J. Michael McIntosh, Sharon Letchworth & Kristen Jordan. (2013) α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology 71, pages 191-203.
Crossref
Crossref
Sylvain Célanire, Benjamin Perry, Robert Lutjens, Sonia Poli & Ian J. Reynolds. 2013. Emerging Drugs and Targets for Parkinson’s Disease. Emerging Drugs and Targets for Parkinson’s Disease
237
265
.
Liang Ye, Xiaolin Guan, Jingwei Tian, Jianzhao Zhang, Guangying Du, Xin Yu, Pengfei Yu, Xiaobo Cen, Wanhui Liu & Youxin Li. (2013) Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats. Food and Chemical Toxicology 56, pages 81-92.
Crossref
Crossref
Nicolas Morin, Laurent Grégoire, Marc Morissette, Sandrine Desrayaud, Baltazar Gomez-Mancilla, Fabrizio Gasparini & Thérèse Di Paolo. (2013) MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology 66, pages 355-364.
Crossref
Crossref
Maryka Quik, Archana Mallela, Matthew Chin, J. Michael McIntosh, Xiomara A. Perez & Tanuja Bordia. (2013) Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiology of Disease 50, pages 30-41.
Crossref
Crossref
Jingwei Tian, Guangying Du, Liang Ye, Xin Yu, Jianzhao Zhang, Hongbo Wang, Pengfei Yu, Fenghua Fu, Wanhui Liu, Youxin Li, Xiaobo Cen & Xiaolin Guan. (2013) Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys. Food and Chemical Toxicology 52, pages 143-152.
Crossref
Crossref
Damien Lemoine, Ruotian Jiang, Antoine Taly, Thierry Chataigneau, Alexandre Specht & Thomas Grutter. (2012) Ligand-Gated Ion Channels: New Insights into Neurological Disorders and Ligand Recognition. Chemical Reviews 112:12, pages 6285-6318.
Crossref
Crossref
Vincenza Bagetta, Carmelo Sgobio, Valentina Pendolino, Giulia Del Papa, Alessandro Tozzi, Veronica Ghiglieri, Carmela Giampà, Elisa Zianni, Fabrizio Gardoni, Paolo Calabresi & Barbara Picconi. (2012) Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease. The Journal of Neuroscience 32:49, pages 17921-17931.
Crossref
Crossref
Osamah B. Al-Baghdadi, Natalie I. Prater, Cornelis J. Van der Schyf & Werner J. Geldenhuys. (2012) Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson’s disease. Bioorganic & Medicinal Chemistry Letters 22:23, pages 7183-7188.
Crossref
Crossref
Susan Duty. (2012) Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease. CNS Drugs 26:12, pages 1017-1032.
Crossref
Crossref
Veronica Ghiglieri, Vincenza Bagetta, Valentina Pendolino, Barbara Picconi & Paolo Calabresi. (2012) Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia. Parkinson's Disease 2012, pages 1-10.
Crossref
Crossref